Compare GME & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GME | IONS |
|---|---|---|
| Founded | 1996 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronics Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7B | 11.9B |
| IPO Year | 2005 | 1996 |
| Metric | GME | IONS |
|---|---|---|
| Price | $22.17 | $77.82 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 22 |
| Target Price | $13.50 | ★ $93.36 |
| AVG Volume (30 Days) | ★ 9.2M | 1.6M |
| Earning Date | 06-09-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 133.33 | 21.71 |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $3,629,900,000.00 | N/A |
| Revenue This Year | $18.98 | N/A |
| Revenue Next Year | N/A | $77.99 |
| P/E Ratio | $29.19 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $19.94 | $32.00 |
| 52 Week High | $35.81 | $86.74 |
| Indicator | GME | IONS |
|---|---|---|
| Relative Strength Index (RSI) | 39.35 | 61.30 |
| Support Level | $20.43 | $75.66 |
| Resistance Level | $23.10 | $82.85 |
| Average True Range (ATR) | 1.16 | 2.45 |
| MACD | -0.36 | 0.28 |
| Stochastic Oscillator | 3.47 | 97.08 |
GameStop Corp offers games, collectibles, and entertainment products through its stores and ecommerce platforms. Its products include Hardware and accessories offering new and pre-owned gaming platforms from the console manufacturers, Software offering new and pre-owned gaming software for current and certain prior generation consoles and sell a wide range of in-game digital currency, digital downloadable content and full-game downloads, and Collectibles consist of apparel, toys, trading cards, gadgets and other retail products for pop culture and technology enthusiasts and collectibles related services, such as submission services for the authentication and grading of trading cards. The company operates its business in three geographic segments: the United States, Australia, and Europe.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).